UPDATE: Bank of America Lowers Auxilium Pharmaceuticals PO to $25 Following 4Q12 Results
Bank of America published a report that reiterated Auxilium Pharmaceuticals (NASDAQ: AUXL) at Buy and trims price objective from $26 to $25.
Bank of America reported that, “We lowered our market growth assumptions for Testim based on recent Rx trends, and modestly increased our share estimates, which assume that AUXL's efforts to stabilize and grow share in 2013 are successful. These changes reduced our 2013E Testim sales to $252mn (from $257mn) and increased our 2014E sales to $302mn (from $293mn). We also lowered our Xiaflex sales estimates for 2013E to $71mn (from $85mn) and $104mn (from $119mn). Our new 2013E EPS is $0.15 (from $0.44) and our 2014E EPS is $0.98 (from $1.02).”
Auxilium Pharmaceuticals shares closed Tuesday at $17.06.
Latest Ratings for AUXL
|Oct 2014||MKM Partners||Downgrades||Buy||Neutral|
|Sep 2014||RBC Capital||Downgrades||Outperform||Sector Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.